These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 17173547)

  • 1. HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse.
    Hauser KF; El-Hage N; Stiene-Martin A; Maragos WF; Nath A; Persidsky Y; Volsky DJ; Knapp PE
    J Neurochem; 2007 Feb; 100(3):567-86. PubMed ID: 17173547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opiate drug use and the pathophysiology of neuroAIDS.
    Hauser KF; Fitting S; Dever SM; Podhaizer EM; Knapp PE
    Curr HIV Res; 2012 Jul; 10(5):435-52. PubMed ID: 22591368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro.
    Viviani B; Corsini E; Binaglia M; Galli CL; Marinovich M
    Neuroscience; 2001; 107(1):51-8. PubMed ID: 11744246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for interactions of HIV and drugs of abuse.
    Nath A; Hauser KF; Wojna V; Booze RM; Maragos W; Prendergast M; Cass W; Turchan JT
    J Acquir Immune Defic Syndr; 2002 Oct; 31 Suppl 2():S62-9. PubMed ID: 12394784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era.
    Chilunda V; Calderon TM; Martinez-Aguado P; Berman JW
    Brain Res; 2019 Dec; 1724():146426. PubMed ID: 31473221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NeuroAIDS, drug abuse, and inflammation: building collaborative research activities.
    Berman JW; Carson MJ; Chang L; Cox BM; Fox HS; Gonzalez RG; Hanson GR; Hauser KF; Ho WZ; Hong JS; Major EO; Maragos WF; Masliah E; McArthur JC; Miller DB; Nath A; O'Callaghan JP; Persidsky Y; Power C; Rogers TJ; Royal W
    J Neuroimmune Pharmacol; 2006 Dec; 1(4):351-99. PubMed ID: 18040811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of opiate-HIV-1 interactions on neurotoxic signaling.
    Hauser KF; El-Hage N; Buch S; Nath A; Tyor WR; Bruce-Keller AJ; Knapp PE
    J Neuroimmune Pharmacol; 2006 Mar; 1(1):98-105. PubMed ID: 18040795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Institute on Drug Abuse symposium report: drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.
    Purohit V; Rapaka R; Frankenheim J; Avila A; Sorensen R; Rutter J
    J Neurovirol; 2013 Apr; 19(2):119-22. PubMed ID: 23456951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.
    Hauser KF; Knapp PE
    Int Rev Neurobiol; 2014; 118():231-313. PubMed ID: 25175867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does drug abuse influence the microglial response in AIDS and HIV encephalitis?
    Arango JC; Simmonds P; Brettle RP; Bell JE
    AIDS; 2004 Jan; 18 Suppl 1():S69-74. PubMed ID: 15075500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NeuroAIDS: retroviral pathology and drugs of abuse.
    Peterson PK; Fox HS
    Adv Exp Med Biol; 2001; 493():259-61. PubMed ID: 11727775
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple Faceted Roles of Cocaine in Potentiation of HAND.
    Cai Y; Yang L; Callen S; Buch S
    Curr HIV Res; 2016; 14(5):412-416. PubMed ID: 27009095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases.
    Yoshioka M; Bradley WG; Shapshak P; Nagano I; Stewart RV; Xin KQ; Srivastava AK; Nakamura S
    Adv Neuroimmunol; 1995; 5(3):335-58. PubMed ID: 8748077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HIV encephalopathy--clinical aspects, neuropathology and pathogenesis].
    Schielke E
    Nervenarzt; 1993 Feb; 64(2):83-90. PubMed ID: 8450899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV Neuropathogenesis in the Presence of a Disrupted Dopamine System.
    Nickoloff-Bybel EA; Calderon TM; Gaskill PJ; Berman JW
    J Neuroimmune Pharmacol; 2020 Dec; 15(4):729-742. PubMed ID: 32506353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction.
    Nath A
    Ann N Y Acad Sci; 2010 Feb; 1187():122-8. PubMed ID: 20201849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroimmunity, drugs of abuse, and neuroAIDS.
    Burdo TH; Katner SN; Taffe MA; Fox HS
    J Neuroimmune Pharmacol; 2006 Mar; 1(1):41-9. PubMed ID: 18040790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HIV-1 neuropathogenesis: therapeutic strategies against neuronal loss induced by gp120/Tat glycoprotein in the central nervous system].
    Merino JJ; Montes ML; Blanco A; Bustos MJ; Oreja-Guevara C; Bayon C; Cuadrado A; Lubrini G; Cambron I; Munoz A; Cebolla S; Gutierrez-Fernandez M; Bernardino JI; Arribas JR; Fiala M
    Rev Neurol; 2011 Jan; 52(2):101-11. PubMed ID: 21271550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS.
    Kaul M; Lipton SA
    J Neuroimmune Pharmacol; 2006 Jun; 1(2):138-51. PubMed ID: 18040780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS.
    Buckner CM; Luers AJ; Calderon TM; Eugenin EA; Berman JW
    J Neuroimmune Pharmacol; 2006 Jun; 1(2):160-81. PubMed ID: 18040782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.